Physician profile
Mohammad Aslam
NPI 1821197708
$17,525.84
in general payments reported to CMS, 2019-2025
33 companies · $2,878 in 2025
The $2,878 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,367 · 2020: $1,297 · 2021: $2,189 · 2022: $1,715 · 2023: $2,764 · 2024: $4,317 · 2025: $2,878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,202 · Travel and Lodging: $1,756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,202.11 |
| Travel and Lodging | $1,756.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,584.58 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,858.09 | 2019-2025 | Jardiance, Tradjenta |
| Angiodynamics, INC. | $1,756.48 | 2024 | Alphavac |
| Novo Nordisk INC | $1,501.06 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,417.36 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $943.85 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $682.19 | 2021-2025 | |
| Pfizer INC. | $645.76 | 2019-2025 | |
| Abbott Laboratories | $614.63 | 2021-2024 | Freestyle Libre 3, Pressurewire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $469.19 | 2023-2025 | Caplyta |
| Amarin Pharma, INC. | $468.54 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $455.93 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $402.60 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Phathom Pharmaceuticals, INC. | $399.29 | 2023-2025 | Voquezna |
| Abbvie INC. | $371.20 | 2021-2025 | Qulipta |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $249.65 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $246.90 | 2024-2025 | Opsumit, Uptravi |
| Sanofi-Aventis U.S. LLC | $208.12 | 2019-2021 | |
| Amgen INC. | $195.53 | 2023-2025 | Repatha, Repatha |
| Global Blood Therapeutics, INC. | $150.21 | 2020-2022 | |
| Intuity Medical INC | $133.91 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $125.00 | 2024 | Inpefa |
| Neurocrine Biosciences, INC. | $124.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $115.64 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $115.23 | 2023 | Acthar |
| Exact Sciences Corporation | $84.95 | 2023-2024 | Cologuard Collection Kit |
| Renalytix Ai, INC. | $44.91 | 2023-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Shield Therapeutics INC | $39.74 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $37.97 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $22.14 | 2025 | Zoryve |
| Genzyme Corporation | $21.13 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.98 | 2022 | |
| Allergan, INC. | $19.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Aslam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.